As we step into 2024, the biotechnology industry stands at a pivotal point, driven by rapid advancements in technology and shifting market dynamics. The past few years have been transformative,…
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has…
Biotechnology company Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM301 series for difficult-to-treat mental health disorders. EB-003 was selected by the company based on data…
A conversation with Enveric Biosciences CEO Joseph Tucker, Ph.D. Two themes have arisen as of late in the clinical trials space, and both collide in this Q&A for an interesting…
The non-partisan Digital Politics Podcast with Karen Jagoda highlights the impact of new technologies on the campaign landscape, how expectations of voters are changing, role of online fundraising, digital and…
In this episode of The Mindfulness Experience Podcast, host Keith Fiveson interviews Dr. Joseph Tucker, the CEO and Director of Enveric Biosciences. Enveric Biosciences is a biotechnology company that is…
Enveric Biosciences has received a Notice of Allowance (NoA) from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the company’s new chemical entity (NCE)…
But perhaps, most importantly, says Kevin Coveney, CFO at Enveric Biosciences, is that the CFO needs to understand their role as a support to the CEO in realising their plans….
Thanks to the Golden Triangle, Britain is great at biotech innovation, it’s just not that good at nurturing this innovation through to the blue-chip stage. This can be attributed to…
A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental…